Be part of the knowledge.
Register

We’re glad to see you’re enjoying ReachMD…
but how about a more personalized experience?

Register for free
  1. Home
  2. Programs
  3. CME/CE

IgG4-RD Case Conversations: Systemic Disease Infiltrating the Skull Base

30 minutes
ReachMD Healthcare Image
Restart
Resume
Choose a format
Take Post-Test
0.50 credits
Completing the pre-test is required to access this content.
Completing the pre-survey is required to view this content.

Ready to Claim Your Credits?

You have attempts to pass this post-test. Take your time and review carefully before submitting.

Good luck!

Details
Presenters
Related
Comments
  • Overview

    In this case, a patient presented with an extensive skull base lesion infiltrating multiple compartments and threatening multiple sensory systems. Drs. John Stone (Chair), Bart Chwalisz, and Marcela Marsiglia discuss how systematic clinical and radiologic evaluation of all compartments in the skull base was crucial to delineate the extent of the disease and reach a mature diagnosis of IgG4-related disease (IgG4-RD). This astute recognition of IgG4-RD, while excluding key mimickers, and prompt intervention with a biologic led to an excellent treatment outcome, preventing misdiagnosis and  unnecessary/inappropriate interventions.

  • Disclosure of Conflicts of Interest

    DISCLOSURE POLICY
    It is the policy of Evolve that faculty and other individuals who are in the position to control the content of this activity disclose any real or apparent financial relationships relating to the topics of this educational activity. Evolve has full policies in place that will identify and mitigate all financial relationships prior to this educational activity.

    The following faculty/staff members have the following financial relationships with ineligible companies.

    John H. Stone, MD, MPH, has had a financial relationship or affiliation with the following ineligible companies in the form of Consultant: AbbVie, Acepodia, Alexion, Alpine Immune Sciences, Amgen, Argenx, Connect Biopharma, CTI BioPharma, Genentech, Horizon Therapeutics, iCell Gene Therapeutics, IQVIA, Merck, Norartis, Polaris, Q32 Bio, Salvina Therapeutics, Sanofi, and ZenasBio. Grant/Research Support: Bristol-Myers Squib, Horizon Therapeutics, and Sanofi.

    Bart K. Chwalisz, MD, has had no financial relationships or affiliations with ineligible companies.

    Marcela Marsiglia, MD, PhD, has had no financial relationships or affiliations with ineligible companies.

    The Evolve staff, planners, and peer reviewer have no financial relationships with ineligible companies.

  • Learning Objectives

    Upon completion of this activity, the participant should be able to:

    • Describe the prevalence, etiology, and pathophysiology of IgG4-related disease
    • Identify the individual organ manifestations/clinical features that may support a diagnosis of IgG4-related disease
    • Outline the diseases and/or conditions whose manifestations have substantial overlap with IgG4-RD
    • Analyze clinical, serological, histopathological, and radiological findings to facilitate early diagnosis of patients with IgG4-related disease
    • Explain how patients with IgG4-RD are currently treated
    • Develop effective co-management strategies to improve outcomes for patients with IgG4-RD
  • Target Audience

    This certified continuing education activity is designed for rheumatologists, nurse practitioners, and physician assistants, as well as ophthalmologists, pathologists and radiologists who diagnose and treat patients involved in the diagnosis and management of IgG4-related disease.

  • Accreditation and Credit Designation Statements

    Provided by Evolve Medical Education  

    Evolve is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

    Evolve designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    The American Medical Association has an agreement of mutual recognition of Continuing Medical Education (CME) credits with the European Union of Medical Specialists (UEMS), the accreditation body for European countries. Physicians interested in converting AMA PRA Category 1 Credit™ to UEMS-European Accreditation Council for Continuing Medical Education CME credits (ECMEC®s) should contact the UEMS at mutualrecognition@uems.eu.

  • Provider(s)/Educational Partner(s)

    Evolve Medical Education LLC (Evolve) is a leader in cultivating health care for patients by educating clinical competence of the health care team. Evolve achieves this by developing and distributing high-quality, evidence-based, valid, independent CME/CE activities in a variety of learning formats. These activities are designed to increase clinician’s knowledge, skills, competence and professional performance as well as to promote professional growth, maintenance of licensure, and support quality change in care of patients.

  • Commercial Support

    This activity is supported by an independent medical education grant from Amgen.

  • Disclaimer

    OFF-LABEL STATEMENT
    This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The opinions expressed in the educational activity are those of the faculty. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

    DISCLAIMER
    The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of Evolve or Amgen.

    This activity is designed for educational purposes. Participants have a responsibility to utilize this information to enhance their professional development to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision-making before applying any information, whether provided here or by others, for any professional use. 

  • System Requirements

    • Supported Browsers (2 most recent versions):
      • Google Chrome for Windows, Mac OS, iOS, and Android
      • Apple Safari for Mac OS and iOS
      • Mozilla Firefox for Windows, Mac OS, iOS, and Android
      • Microsoft Edge for Windows
    • Recommended Internet Speed: 5Mbps+

  • Publication Dates

    Release Date:

    Expiration Date:

Recommended
Details
Presenters
Related
Comments
  • Overview

    In this case, a patient presented with an extensive skull base lesion infiltrating multiple compartments and threatening multiple sensory systems. Drs. John Stone (Chair), Bart Chwalisz, and Marcela Marsiglia discuss how systematic clinical and radiologic evaluation of all compartments in the skull base was crucial to delineate the extent of the disease and reach a mature diagnosis of IgG4-related disease (IgG4-RD). This astute recognition of IgG4-RD, while excluding key mimickers, and prompt intervention with a biologic led to an excellent treatment outcome, preventing misdiagnosis and  unnecessary/inappropriate interventions.

  • Disclosure of Conflicts of Interest

    DISCLOSURE POLICY
    It is the policy of Evolve that faculty and other individuals who are in the position to control the content of this activity disclose any real or apparent financial relationships relating to the topics of this educational activity. Evolve has full policies in place that will identify and mitigate all financial relationships prior to this educational activity.

    The following faculty/staff members have the following financial relationships with ineligible companies.

    John H. Stone, MD, MPH, has had a financial relationship or affiliation with the following ineligible companies in the form of Consultant: AbbVie, Acepodia, Alexion, Alpine Immune Sciences, Amgen, Argenx, Connect Biopharma, CTI BioPharma, Genentech, Horizon Therapeutics, iCell Gene Therapeutics, IQVIA, Merck, Norartis, Polaris, Q32 Bio, Salvina Therapeutics, Sanofi, and ZenasBio. Grant/Research Support: Bristol-Myers Squib, Horizon Therapeutics, and Sanofi.

    Bart K. Chwalisz, MD, has had no financial relationships or affiliations with ineligible companies.

    Marcela Marsiglia, MD, PhD, has had no financial relationships or affiliations with ineligible companies.

    The Evolve staff, planners, and peer reviewer have no financial relationships with ineligible companies.

  • Learning Objectives

    Upon completion of this activity, the participant should be able to:

    • Describe the prevalence, etiology, and pathophysiology of IgG4-related disease
    • Identify the individual organ manifestations/clinical features that may support a diagnosis of IgG4-related disease
    • Outline the diseases and/or conditions whose manifestations have substantial overlap with IgG4-RD
    • Analyze clinical, serological, histopathological, and radiological findings to facilitate early diagnosis of patients with IgG4-related disease
    • Explain how patients with IgG4-RD are currently treated
    • Develop effective co-management strategies to improve outcomes for patients with IgG4-RD
  • Target Audience

    This certified continuing education activity is designed for rheumatologists, nurse practitioners, and physician assistants, as well as ophthalmologists, pathologists and radiologists who diagnose and treat patients involved in the diagnosis and management of IgG4-related disease.

  • Accreditation and Credit Designation Statements

    Provided by Evolve Medical Education  

    Evolve is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

    Evolve designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    The American Medical Association has an agreement of mutual recognition of Continuing Medical Education (CME) credits with the European Union of Medical Specialists (UEMS), the accreditation body for European countries. Physicians interested in converting AMA PRA Category 1 Credit™ to UEMS-European Accreditation Council for Continuing Medical Education CME credits (ECMEC®s) should contact the UEMS at mutualrecognition@uems.eu.

  • Provider(s)/Educational Partner(s)

    Evolve Medical Education LLC (Evolve) is a leader in cultivating health care for patients by educating clinical competence of the health care team. Evolve achieves this by developing and distributing high-quality, evidence-based, valid, independent CME/CE activities in a variety of learning formats. These activities are designed to increase clinician’s knowledge, skills, competence and professional performance as well as to promote professional growth, maintenance of licensure, and support quality change in care of patients.

  • Commercial Support

    This activity is supported by an independent medical education grant from Amgen.

  • Disclaimer

    OFF-LABEL STATEMENT
    This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The opinions expressed in the educational activity are those of the faculty. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

    DISCLAIMER
    The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of Evolve or Amgen.

    This activity is designed for educational purposes. Participants have a responsibility to utilize this information to enhance their professional development to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision-making before applying any information, whether provided here or by others, for any professional use. 

  • System Requirements

    • Supported Browsers (2 most recent versions):
      • Google Chrome for Windows, Mac OS, iOS, and Android
      • Apple Safari for Mac OS and iOS
      • Mozilla Firefox for Windows, Mac OS, iOS, and Android
      • Microsoft Edge for Windows
    • Recommended Internet Speed: 5Mbps+

  • Publication Dates

    Release Date:

    Expiration Date:

Schedule11 Dec 2024